|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.22 USD | -1.63% |
|
-8.86% | -53.54% |
| May. 30 | Top Premarket Gainers | MT |
| May. 29 | Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences | MT |
Jaguar Health, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 41.3 million compared to USD 47.45 million a year ago. Basic loss per share from continuing operations was USD 107.3998 compared to USD 2,170.7957 a year ago.
Diluted loss per share from continuing operations was USD 107.3998 compared to USD 2,170.7957 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -53.54% | 20.63M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
JAGUAR HEALTH, INC. 
